Features of the immune response formation to SARS-CoV-2 in patients who have recovered from COVID-19

Authors

  • H.L. Kyseliova DILA Medical Laboratory, Kyiv, Ukraine, Ukraine
  • I.A. Anastasii Bogomolets National Medical University, Kyiv, Ukraine, Ukraine
  • O.B. Tonkovyd DILA Medical Laboratory, Kyiv, Ukraine, Ukraine
  • V.M. Isaiev DILA Medical Laboratory, Kyiv, Ukraine, Ukraine
  • I.V. Sidorova DILA Medical Laboratory, Kyiv, Ukraine, Ukraine
  • K.V. Voronova DILA Medical Laboratory, Kyiv, Ukraine, Ukraine

DOI:

https://doi.org/10.22141/2312-413X.9.3.2021.236225

Keywords:

coronavirus disease, COVID-19, antibodies, immunoglobulins, immune response

Abstract

This study was conducted to assess the presence of an immune response in staff of DILA Medical Laboratory who have recovered from COVID-19, to study the features of monitoring indicators in different clinical variants of the disease. The obtained results allowed analyzing various types of the immune response in patients with a new coronavirus disease. In staff who has reco­vered from COVID-19, an immune response study was performed by determining the presence of immunoglobulins M and G to va­rious coronavirus target proteins by a semiquantitative method on a chemiluminescence immunoassay analyzer. The findings allowed us to assess not only the intensity of the immune response, but also the relationship with clinical manifestations, disease duration, age, which will be important for further comparative analysis with the immune response of vaccinated employees. The findings showed that most patients with COVID-19 produce protective antibo­dies, more often to the S-target, and also allowed determining the ave­rage duration of circulation of both immunoglobulin M and G antibodies.

References

https://www.cdc.gov/coronavirus/2019-ncov/testing/serology-overview.html.

Immune Memory after COVID-19 Research yields insights into antibody immunity after infectionBy RACHEL LEESON | Ragon Institute Communications February 17, 2021 ResearchCare Delivery. https://hms.harvard.edu/news/immune-memory-after-covid-19.

Discrete SARS-CoV-2 antibody titers track with functional humoral stability. 15 February 2021. https://www.nature.com/articles/s41467-021-21336-8.

https://connects.catalyst.harvard.edu/Profiles/display/Person/83846.

Роббиани Д.Ф. и др. Конвергентные ответы антител на SARS-CoV-2 у выздоравливающих людей. Nature. 2020. 584. 437-442.

Айер А.С. и др. Устойчивость и ослабление ответов человеческих антител на рецептор-связывающий домен спайкового белка SARS-CoV-2 у пациентов с COVID-19. Sci Immunol. 2020. eabe0367.

Tillett R. et al. Геномные доказательства случая повторного заражения SARS-CoV-2 SSRN. 2020.

Лонг Q.X. et al. Ответы антител на SARS-CoV-2 у пациентов с COVID-19. Nat. Med. 2020. 26. 845-848.

Diagnostic testing for SARS-CoV-2: Interim Guidance, 11 September 2020. https://apps.who.int/iris/bitstream/handle/10665/334254/WHO-2019-nCoV-laboratory-2020.6-rus.pdf.

Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. China CDC Weekly. 2020. 2(8). 113-122.

Clinical and immunological assessment of asymptoma­tic SARS-CoV-2 infections. 2020 Aug. 26(8). 1200-1204. https://pubmed.ncbi.nlm.nih.gov/32555424. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.

Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PLoS One. 2020 Oct 21. 15(10). e0241104. https://pubmed.ncbi.nlm.nih.gov/33085715. doi: 10.1371/journal.pone.0241104. eCollection 2020.

Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK2021 Apr 27. 8. 642723. doi: 10.3389/fmed.2021.642723. eCollection 2021. https://pubmed.ncbi.nlm.nih.gov/33987193.

SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. 2021 Feb 24. 223(4). 589-599. https://pubmed.ncbi.nlm.nih.gov/33247924. doi:10.1093/infdis/jiaa737.

https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019/advice-for-public/q-a-coronaviruses.

https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-how-is-it-transmitted.

Hopkins C. Loss of sense of smell as marker of COVID-19 infection. https://www.entuk.org/sites/default/files/files/Loss%20of%20sense%20of%20smell%20as%20marker%20of%20COVID.pdf.

https://www.cdc.gov/coronavirus/2019-ncov/downloads/COVID-19-global-faith-community-leaders_russian.pdf.

Клиническое исследование препаратов для лечения COVID-19 «Solidarity». https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments.

Post-COVID Conditions Updated Apr. 8, 2021. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html.

https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html.

Published

2021-07-13

Issue

Section

Original Researches